Clinical Trial: Atomized Intranasal Ketorolac at 30 mg Versus 20 mg for the Treatment of Acute Pain in the Emergency Department: A Randomized Non-inferiority Trial

U.S., Sept. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07816302) titled 'Atomized Intranasal Ketorolac at 30 mg Versus 20 mg for the Treatment of Acute Pain in the Emergency Department: A Randomized Non-inferiority Trial' on Sept. 06.

Brief Summary: This study aims to compare the analgesic effectiveness and side effects of intranasal ketorolac at 30 mg Versus 20 mg for the Treatment of Acute moderate and severe Pain in the Emergency Department.

Study Start Date: Oct. 10

Study Type: INTERVENTIONAL

Condition: Pain Ketorolac Intranasal Drug Administration

Intervention: DRUG: 20mg intranasal ketorolac

20 mg (1cc) ketorolac will be administered intranasally using mucosal atomizer. Half dose (0.5 cc) i...